These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 8953106)

  • 1. Comparison of activities of trovafloxacin (CP-99,219) and five other agents against 585 anaerobes with use of three media.
    Hecht DW; Osmolski JR
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S44-50. PubMed ID: 8953106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro susceptibility of anaerobes to quinolones in the United States.
    Hecht DW; Wexler HM
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S2-8. PubMed ID: 8953099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro activities of trovafloxacin (CP 99,219) and other antimicrobials against clinically significant anaerobes.
    Aldridge KE; Ashcraft D; Bowman KA
    Antimicrob Agents Chemother; 1997 Feb; 41(2):484-7. PubMed ID: 9021215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria.
    Nord CE
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S15-8. PubMed ID: 8953101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of gemifloxacin (SB 265805) against anaerobes.
    Goldstein EJ; Citron DM; Warren Y; Tyrrell K; Merriam CV
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2231-5. PubMed ID: 10471570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergic activity, for anaerobes, of trovafloxacin with clindamycin or metronidazole: chequerboard and time-kill methods.
    Ednie LM; Credito KL; Khantipong M; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 2000 May; 45(5):633-8. PubMed ID: 10797085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes.
    Spangler SK; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():23-7. PubMed ID: 9222066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calibration of the disk diffusion test for trovafloxacin susceptibility testing of four anaerobic species.
    Kronvall G; Holst E
    Clin Microbiol Infect; 2000 Apr; 6(4):195-201. PubMed ID: 11168107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria.
    Wexler HM; Molitoris E; Molitoris D; Finegold SM
    Antimicrob Agents Chemother; 1996 Sep; 40(9):2232-5. PubMed ID: 8878617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria.
    Edlund C; Sabouri S; Nord CE
    Eur J Clin Microbiol Infect Dis; 1998 Mar; 17(3):193-5. PubMed ID: 9665302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility of anaerobic bacteria to PD 131628.
    Nord CE; Hagelbäck A
    Eur J Clin Microbiol Infect Dis; 1992 Jan; 11(1):68-71. PubMed ID: 1314176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of grepafloxacin (OPC-17116) against anaerobic bacteria.
    Wexler HM; Molitoris E; Finegold SM
    Diagn Microbiol Infect Dis; 1994 Jun; 19(2):129-33. PubMed ID: 7805357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of meropenem compared with imipenem, metronidazole, ampicillin, and ampicillin/sulbactam against anaerobes.
    Schumacher U; Manncke B; Gerbracht K; Werner H
    Arzneimittelforschung; 1994 Jul; 44(7):859-62. PubMed ID: 7945523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of 497 clinical isolates of gram-negative anaerobes to trovafloxacin and eight other antibiotics.
    Rotimi VO; Mokaddas EM; Jamal WY; Khodakhast FB; Verghese TL; Sanyal SC
    J Chemother; 1999 Oct; 11(5):349-56. PubMed ID: 10632380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria.
    Goldstein EJ; Citron DM
    Antimicrob Agents Chemother; 1992 May; 36(5):1158-62. PubMed ID: 1324640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of the new quinolone BAY y 3118 against anaerobic bacteria.
    Nord CE; Lindmark A; Persson I
    Eur J Clin Microbiol Infect Dis; 1993 Aug; 12(8):640-2. PubMed ID: 8223667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.
    Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1993 Aug; 37(8):1649-54. PubMed ID: 8215278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trovafloxacin compared with levofloxacin, ofloxacin, ciprofloxacin, azithromycin and clarithromycin against unusual aerobic and anaerobic human and animal bite-wound pathogens.
    Goldstein EJ; Citron DM; Hudspeth M; Hunt Gerardo S; Merriam CV
    J Antimicrob Chemother; 1998 Mar; 41(3):391-6. PubMed ID: 9578167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes.
    Spangler SK; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2471-6. PubMed ID: 7840591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vitro activities of clinafloxacin and trovafloxacin against 1,000 isolates of bacteroides fragilis group: effect of the medium on test results.
    Snydman DR; Jacobus NV; McDermott LA; Supran SE
    Antimicrob Agents Chemother; 2000 Jun; 44(6):1710-2. PubMed ID: 10817736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.